Answers are grounded in this paper and cite their sources.
Despite mounting evidence emphasizing the role of abnormal subchondral bone remodeling in the progression of osteoarthritis (OA), clinical translation has produced disappointing results. Here, we demonstrate an increased expression of Wnt1, a key Wnt ligand with potent osteoanabolic effects, during OA progression in human and murine subchondral bone. Temporarily overexpressing Wnt1 in osteoblasts in the early phase after anterior cruciate ligament transection (ACLT)-induced OA has no effect on cartilage degeneration; however, it contributes to increased subchondral bone mass and alleviates subchondral bone loss. In contrast, late-phase induction of Wnt1 in osteoblasts exacerbates OA severity by inducing aberrant subchondral bone sclerosis, where inflammation-induced secreted frizzled-related protein 2 (Sfrp2) in the subchondral bone potentiates the harmful effects of Wnt1. Moreover, mice with a global inactivating Wnt1 G177C mutation, which clinically causes osteogenesis imperfecta type XV, display low subchondral bone mass, are resistant to ACLT-induced subchondral bone loss and exhibit attenuated OA progression. Taken together, these findings identify a pathophysiological role for Wnt1 in subchondral bone remodeling and OA progression that could represent a promising therapeutic target.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: